Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer

Future Oncology

Volumn 7, Issue 6, 2011, Pages 727-736

  Guppy, Amy ^a   Jamal Hanjani, Mariam ^b   Pickering, Lisa ^b  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

AMPK; breast cancer; diabetes mellitus; insulin; metformin

Indexed keywords

AMILORIDE; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE; DIGOXIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; INSULIN; INSULIN RECEPTOR; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; MITOGEN ACTIVATED PROTEIN KINASE; MORPHINE; NIFEDIPINE; ORGANIC CATION TRANSPORTER 1; PROCAINAMIDE; PROTEIN KINASE LKB1; QUINIDINE; QUININE; RANITIDINE; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; TRASTUZUMAB; TUBERIN; UNINDEXED DRUG; VANCOMYCIN;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; BREAST BIOPSY; BREAST CANCER; CANCER INHIBITION; CARCINOGENESIS; CARDIOMYOPATHY; CELL CYCLE; CELL CYCLE REGULATION; CELL PROLIFERATION; COLON CANCER; DIABETES MELLITUS; DIARRHEA; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; GENE EXPRESSION; GLUCONEOGENESIS; HUMAN; HYPERGLYCEMIA; IMAGING; INSULIN BLOOD LEVEL; KIDNEY CARCINOMA; LACTIC ACIDOSIS; LIFESTYLE; LIPID METABOLISM; LYMPHOMA; METABOLIC SYNDROME X; MITOSIS INHIBITION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; RECURRENCE RISK; RESISTANCE TRAINING; SIGNAL TRANSDUCTION; SOLID TUMOR; STRESS; TRIPLE NEGATIVE BREAST CANCER; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN;

EID: 79959455071     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.49     Document Type: Article

References (65)

1. Rothwell PM: Treating individuals 2 Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet 365(9454), 176-186 (2005) (Pubitemid 40091809)
2. Goodwin PJ, Stambolic V, Lemieux J et al.: Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res. Treat. 126(1), 215-220 (2011)
3. Maki RG: Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J. Clin. Oncol. 28(33), 4985-4995 (2010)
4. Wolf I, Sadetzki S, Catane R, Karasik A, Kaufman B: Diabetes mellitus and breast cancer. Lancet Oncol. 6(2), 103-111 (2005) (Pubitemid 40197704)
5. Larsson SC, Mantzoros CS, Wolk A: Diabetes mellitus and risk of breast cancer: a meta-analysis. Int. J. Cancer 121(4), 856-862 (2007) (Pubitemid 47106217)
6. Del Giudice ME, Fantus IG, Ezzat S, Mckeown-Eyssen G, Page D, Goodwin PJ: Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res. Treat. 47(2), 111-120 (1998) (Pubitemid 28046082)
7. Goodwin PJ, Ennis M, Pritchard KI et al.: Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J. Clin. Oncol. 20(1), 42-51 (2002) (Pubitemid 34032594)
8. Pollak M: Insulin resistance, estimated by C-peptide level, is associated with reduced event-free survival for post-menopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. J. Clin. Oncol. 24(Suppl. 18) Abstract 524 (2006)
9. Goodwin PJ, Ennis M, Bahl M et al.: High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res. Treat. 114(3), 517-525 (2009)
10. Alberti KG, Eckel RH, Grundy SM et al.: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120(16), 1640-1645 (2009)
11. Healy LA, Ryan AM, Carroll P et al.: Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin. Oncol. (R. Coll. Radiol.) 22(4), 281-288 (2010)
12. Maiti B, Kundranda MN, Spiro TP, Daw HA: The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res. Treat. 121(2), 479-483 (2010)
13. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S: Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int. J. Cancer 119(1), 236-238 (2006)
14. Carboni JM, Lee AV, Hadsell DL et al.: Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res. 65(9), 3781-3787 (2005) (Pubitemid 40616356)
15. Frasca F, Pandini G, Vigneri R, Goldfine ID: Insulin and hybrid insulin/ IGF receptors are major regulators of breast cancer cells. Breast Dis. 17, 73-89 (2003) (Pubitemid 38180810)
16. Zha J, Lackner MR: Targeting the insulin-like growth factor receptor-1R pathway for cancer therapy. Clin. Cancer Res. 16(9), 2512-2517 (2010)
17. Law JH, Habibi G, Hu K et al.: Phosphorylated insulin-like growth factor-I/ insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 68(24), 10238-10246 (2008)
18. Rosenzweig SA, Atreya HS: Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem. Pharmacol. 80(8), 1115-1124 (2010)
19. Ryan PD, Goss PE: The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 13(1), 16-24 (2008) (Pubitemid 351206693)
20. Ligibel JA, Campbell N, Partridge A et al.: Impact of a mixed strength and endurance exercise intervention on insulin levels in breast cancer survivors. J. Clin. Oncol. 26(6), 907-912 (2008) (Pubitemid 351398083)
21. Chlebowski RT, Blackburn GL, Thomson CA et al.: Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J. Natl Cancer Inst. 98(24), 1767-1776 (2006) (Pubitemid 46017928)
22. Goodwin PJ: Metformin lowers fasting insulin levels in hyperinsulinemia early stage breast cancer patients: Results of a Phase II study. Breast Cancer Res. Treat. 100, S109(Suppl. 1) Abstract 2085 (2006)
23. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503), 1304-1305 (2005) (Pubitemid 40813563)
24. Bowker SL, Majumdar SR, Veugelers P, Johnson JA: Increased cancer-related mortality for patients with Type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29(2), 254-258 (2006) (Pubitemid 44106500)
25. Landman GW, Kleefstra N, Van Hateren KJ, Groenier KH, Gans RO, Bilo HJ: Metformin associated with lower cancer mortality in Type 2 diabetes: ZODIAC-16 Diabetes Care 33(2), 322-326 (2010)
26. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM: New users of metformin are at low risk of incident cancer: a cohort study among people with Type 2 diabetes. Diabetes Care 32(9), 1620-1625 (2009)
27. Currie CJ, Poole CD, Gale EA: The influence of glucose-lowering therapies on cancer risk in Type 2 diabetes. Diabetologia 52(9), 1766-1777 (2009)
28. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6), 1304-1308 (2010)
29. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66(21), 10269-10273 (2006) (Pubitemid 44799743)
30. Shaw RJ, Lamia KA, Vasquez D et al.: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310(5754), 1642-1646 (2005) (Pubitemid 41780780)
31. Giardiello FM, Brensinger JD, Tersmette AC et al.: Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 119(6), 1447-1453 (2000) (Pubitemid 32198669)
32. Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG: Insulin-lowering effects of metformin in women with early breast cancer. Clin. Breast Cancer 8(6), 501-505 (2008)
33. Rozengurt E, Sinnett-Smith J, Kisfalvi K: Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin. Cancer Res. 16(9), 2505-2511 (2010)
34. Ning J, Clemmons DR: AMP-activated protein kinase inhibits IGF-I signaling and protein synthesis in vascular smooth muscle cells via stimulation of insulin receptor substrate 1 S794 and tuberous sclerosis 2 S1345 phosphorylation. Mol. Endocrinol. 24(6), 1218-1229 (2010)
35. Zhou G, Myers R, Li Y et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108(8), 1167-1174 (2001) (Pubitemid 32995375)
36. Hawley SA, Gadalla AE, Olsen GS, Hardie DG: The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51(8), 2420-2425 (2002) (Pubitemid 34827390)
37. Cazzaniga M, Bonanni B, Guerrieri-Gonzaga A, Decensi A: Is it time to test metformin in breast cancer clinical trials? Cancer Epidemiol. Biomarkers Prev. 18(3), 701-705 (2009)
38. Bachman KE, Argani P, Samuels Y et al.: The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3(8), 772-775 (2004) (Pubitemid 41351083)
39. Kondo Y, Kanzawa T, Sawaya R, Kondo S: The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5(9), 726-734 (2005) (Pubitemid 41486365)
40. Wang W, Guan KL: AMP-activated protein kinase and cancer. Acta Physiol. (Oxf.) 196(1), 55-63 (2009)
41. Ben Sahra I, Laurent K, Giuliano S et al.: Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 70(6), 2465-2475 (2010)
42. Bailey CJ, Turner RC: Metformin. N. Engl. J. Med. 334(9), 574-579 (1996) (Pubitemid 126537875)
43. Ben Sahra I, Laurent K, Loubat A et al.: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27(25), 3576-3586 (2008) (Pubitemid 351793803)
44. Alimova IN, Liu B, Fan Z et al.: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8(6), 909-915 (2009)
45. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat. Rev. Cancer 8(12), 915-928 (2008)
46. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67(22), 10804-10812 (2007) (Pubitemid 350145909)
47. Bojkova B, Orendas P, Garajova M et al.: Metformin in chemically-induced mammary carcinogenesis in rats. Neoplasma 56(3), 269-274 (2009)
48. Phoenix KN, Vumbaca F, Claffey KP: Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERa negative MDA-MB-435 breast cancer model. Breast Cancer Res. Treat. 113(1), 101-111 (2009)
49. Liu B, Fan Z, Edgerton SM et al.: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13), 2031-2040 (2009)
50. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K: Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69(19), 7507-7511 (2009)
51. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8(1), 88-96 (2009)
52. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA: The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann. Oncol. 20(3), 592-595 (2009)
53. Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA: mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb)Clin. Transl Oncol. 11(7), 455-459 (2009)
54. Xia W, Bisi J, Strum J et al.: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res. 66(3), 1640-1647 (2006) (Pubitemid 43259948)
55. Zhang L, He H, Balschi JA: Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration. Am. J. Physiol. Heart Circ. Physiol. 293(1), H457-H466 (2007) (Pubitemid 47105103)
56. Shell SA, Lyass L, Trusk PB, Pry KJ, Wappel RL, Bacus SS: Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells. Cell Cycle 7(12), 1769-1775 (2008) (Pubitemid 351988742)
57. Phoenix KN, Vumbaca F, Fox MM, Evans R, Claffey KP: Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy. Breast Cancer Res. Treat. 123(2), 333-344 (2010)
58. Jiralerspong S, Palla SL, Giordano SH et al.: Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J. Clin. Oncol. 27(20), 3297-3302 (2009)
59. Martin-Castillo B, Dorca J, Vazquez- Martin A et al.: Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology. Ann. Oncol. 21(1), 187-189 (2010)
60. Muti P, Berrino F, Krogh V et al.: Metformin, diet and breast cancer: an avenue for chemoprevention. Cell Cycle 8(16), 2661 (2009)
61. Hezel AF, Bardeesy N: LKB1; linking cell structure and tumor suppression. Oncogene 27(55), 6908-6919 (2008)
62. Eechoute K, Sparreboom A, Burger H et al.: Drug transporters and imatinib treatment: implications for clinical practice. Clin. Cancer Res. 17(3), 406-415 (2010)
63. Legro RS, Barnhart HX, Schlaff WD et al.: Ovulatory response to treatment of polycystic ovary syndrome is associated with a polymorphism in the STK11 gene. J. Clin. Endocrinol. Metab. 93(3), 792-800 (2008) (Pubitemid 351398555)
64. Glamoclija U, Jevric-Causevic A: Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics. Acta Pharm. 60(4), 387-406 (2010).
65. Ozulker T, Ozulker F, Mert M, Ozpacaci T: Clearance of the high intestinal (18)F-FDG uptake associated with metformin after stopping the drug. Eur. J. Nucl. Med. Mol. Imaging 37(5), 1011-1017 (2010).